![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences Promotes Karin Hehenberger, M.D., Ph.D., to Executive Vice President and Chief Medical Officer
April 25, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., April 25, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences Announces Independent Data Monitoring Committee Recommendation to Continue Falk Phase 2 Trial of TSO in Crohn's Disease
April 24, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., April 24, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences to Present at the 19th Annual Future Leaders in the Biotech Industry Conference
April 12, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., April 12, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2011
March 29, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., March 29, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences Signs Collaboration Agreement With Dr. Falk Pharma and OvaMed for the Development of TSO for Crohn's Disease
March 22, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., March 22, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences to Report Fourth Quarter and Full Year 2011 Financial Results
March 20, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., March 20, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences to Host Analyst & Investor Event in New York City
March 13, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., March 13, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences to Present at the 24th Annual ROTH Conference
March 08, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., March 8, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences to Present at the Cowen and Co. 32nd Annual Health Care Conference
March 01, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., March 1, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
![Coronado Biosciences logo](/news-release/logo/213560/0/213560.jpg?lastModified=12%2F09%2F2016%2023%3A47%3A03&size=2)
Coronado Biosciences Announces Phase 1 Clinical Trial Results for TSO in Crohn's Disease
February 28, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., Feb. 28, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...